Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374630 · ClinicalTrials.gov registry record · Phase 2
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
A Phase 2 study, sponsored by Laekna Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT04374630 is a Phase 2 study that has completed, run by Laekna Limited. The registered enrollment target is 150 participants.
The verdict
NCT04374630, a Phase 2 study, has completed, sponsored by Laekna Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.
Interventions
- DRUG Paclitaxel
- DRUG Afuresertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374630
The ClinicalTrials.gov registry entry for NCT04374630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laekna Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT04374630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374630 about?
NCT04374630 is a clinical study titled "Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian". Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in pati...
What is the current status of trial NCT04374630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2020-06-09. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT04374630?
The interventions under investigation include: Paclitaxel (DRUG), Afuresertib (DRUG).
Who is sponsoring clinical trial NCT04374630?
This trial is sponsored by Laekna Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.